Bowel Disease Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Bowel Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 129 trials

Recruiting
Phase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Indeterminate Colitis+1 more
University of North Carolina, Chapel Hill200 enrolled5 locationsNCT07237516
Recruiting

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

Crohn's DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag Ltd.220 enrolled1 locationNCT07242248
Recruiting

A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany

Crohn's DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag G.m.b.H400 enrolled1 locationNCT07102368
Recruiting

Immune Regulation in Ulcerative Colitis or Crohn s Disease

Ulcerative ColitisInflammatory Bowel DiseaseChrohn's Disease
National Institute of Allergy and Infectious Diseases (NIAID)1,000 enrolled1 locationNCT00001184
Recruiting
Phase 2

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

Crohn's DiseaseUlcerative Colitis (UC)Inflammatory Bowel Disease (IBD)
Mirador Therapeutics, Inc.140 enrolled66 locationsNCT07113522
Recruiting
Phase 2

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

ColitisInflammatory Bowel DiseasesUlcerative Colitis+1 more
Spyre Therapeutics, Inc.645 enrolled126 locationsNCT07012395
Recruiting
Phase 2

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

COVID-19Inflammatory Bowel DiseaseRheumatoid Arthritis (RA)+5 more
McGill University Health Centre/Research Institute of the McGill University Health Centre660 enrolled3 locationsNCT06599658
Recruiting
Phase 2

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Inflammatory Bowel DiseasesCrohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)385 enrolled159 locationsNCT06226883
Recruiting

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

Inflammatory Bowel DiseasesHeart DiseasesAutoimmune Disease+5 more
University of Chicago1,200 enrolled1 locationNCT01280825
Recruiting
Phase 3

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Inflammatory Bowel DiseasesCrohn's DiseaseUlcerative Colitis+1 more
Eli Lilly and Company150 enrolled63 locationsNCT04844606
Recruiting

Development of New Diagnostic Tools in Capsule Endoscopy

TumorCeliac DiseaseCrohn Disease+2 more
Assistance Publique - Hôpitaux de Paris10,000 enrolled1 locationNCT06152289
Recruiting

Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease

IBD (Inflammatory Bowel Disease)Stricture; BowelCD - Crohn's Disease
Second Affiliated Hospital, School of Medicine, Zhejiang University100 enrolled1 locationNCT07444060
Recruiting
Not Applicable

The Influence of a Fasting Mimicking Diet on Ulcerative Colitis

Ulcerative ColitisInflammatory Bowel DiseaseDiet Modification
Stanford University75 enrolled1 locationNCT03615690
Recruiting
Not Applicable

Fermented Food-Supplemented Diet in Ulcerative Colitis

Inflammatory Bowel DiseasesUlcerative ColitisDiet Modification
Stanford University21 enrolled1 locationNCT04401605
Recruiting
Not Applicable

The Assessment of Infrared Treatment for Crohn's Disease

Inflammatory Bowel DiseasesCrohn DiseaseIBD
Shmuel Kivity, MD40 enrolled1 locationNCT06146816
Recruiting

Nutrition and Clinical Outcomes in IBD

SarcopeniaInflammatory Bowel DiseasesCrohn Disease+2 more
Barts & The London NHS Trust300 enrolled1 locationNCT06550310
Recruiting
Phase 3

Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis

Inflammatory Bowel DiseasesUlcerative Colitis
Andreas Stallmach129 enrolled20 locationsNCT03843385
Recruiting

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Ulcerative Colitis (UC)Crohn Disease (CD)Inflammatory Bowel Disease (IBD)+1 more
TIDHI Innovation Inc.200 enrolled9 locationsNCT07245394
Recruiting

Impact of a Structured Therapeutic Education Session on the Practice of Adapted Physical Activity in Chronic Inflammatory Bowel Diseases

Chronic Inflammatory Bowel Disease
University Hospital, Toulouse71 enrolled1 locationNCT07305454